ABVX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

8 Analyst Rating

Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is 129.25 USD with a low forecast of 101.00 USD and a high forecast of 176.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 120.780

Low

101.00

Averages

129.25

High

176.00

Current: 120.780

Low

101.00

Averages

129.25

High

176.00

Truist

Gregory Renza

Buy

initiated

$140

2025-11-24

Reason

Truist

Gregory Renza

Price Target

$140

2025-11-24

initiated

Buy

Reason

Truist analyst Gregory Renza initiated coverage of Abivax with a Buy rating and $140 price target. Following a second-half re-rate from phase 3 induction data in ulcerative colitis, investors are focused on obefazimod's increasing value proposition and set-up for key phase 3 UC maintenance data in Q2 of 2026 and phase 2b induction topline in Crohn's disease coming the second half of 2026, the analyst tells investors in a research note. Obefazimod represents an unusual mechanism of action, which the firm views as being backed by preclinical and clinical evidence indicating broad immunological effects, Truist added.

Wolfe Research

Outperform

initiated

$176

2025-11-05

Reason

Wolfe Research

Price Target

$176

2025-11-05

initiated

Outperform

Reason

Wolfe Research initiated coverage of Abivax with an Outperform rating and $176 price target. The company's odds of success in Crohn's disease may be higher than that of ulcerative colitis, the analyst tells investors in a research note. The firm says that with ulcerative colitis already succeeding, and with obefazimod having a better mechanism for Crohn's disease, the Crohn's readout is a better catalyst in 2026.

Citizens JMP

Outperform

maintain

$95 -> $114

2025-09-25

Reason

Citizens JMP

Price Target

$95 -> $114

2025-09-25

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Abivax to $114 from $95 and keeps an Outperform rating on the shares after the company announced that results from the obefazimod Phase 3 induction trials will be presented next month. The firm believes the Phase 3 results can reinforce the strength of obefazimod's efficacy, and increase conviction in its multi-billion dollar sales potential. In anticipation, Citizens increased the drug's peak sales estimates.

Morgan Stanley

NULL -> Overweight

upgrade

$71 -> $101

2025-09-12

Reason

Morgan Stanley

Price Target

$71 -> $101

2025-09-12

upgrade

NULL -> Overweight

Reason

Morgan Stanley raised the firm's price target on Abivax to $101 from $71 and keeps an Overweight rating on the shares. After the company reported first half results and attended the firm's Global Healthcare Conference, the analyst sees higher odds of success for the Crohn's indication for obefazimod following discussions with management.

Piper Sandler

NULL

Overweight

upgrade

$70 -> $112

2025-07-29

Reason

Piper Sandler

Price Target

$70 -> $112

2025-07-29

upgrade

NULL

Overweight

Reason

Piper Sandler raised the firm's price target on Abivax to $112 from $70 and keeps an Overweight rating on the shares. After fully digesting obefazimod Phase 3 induction data in ulcerative colitis, the firm thinks it's appropriate to layer in revenue in early-line UC, and doing so essentially doubles its U.S. UC revenue estimate to EUR 2,656M in 2035. Thus, Piper still believes there's significant upside that can make its way into the stock heading into key data events.

Citizens JMP

Jason Butler

Outperform

upgrade

$33 -> $95

2025-07-23

Reason

Citizens JMP

Jason Butler

Price Target

$33 -> $95

2025-07-23

upgrade

Outperform

Reason

Citizens JMP analyst Jason Butler raised the firm's price target on Abivax to $95 from $33 and keeps an Outperform rating on the shares. "Stellar" Phase 3 results for obefazimod in ulcerative colitis support the potential for broad and early use in clinical practice, the analyst tells investors in a research note. The positive results from the two Phase 3 induction trials are highly compelling, with a pooled, placebo-adjusted clinical remission rate of 16.4% and a clean safety and tolerability profile, the firm says.

Valuation Metrics

The current forward P/E ratio for Abivax SA (ABVX.O) is -38.35, compared to its 5-year average forward P/E of -8.11. For a more detailed relative valuation and DCF analysis to assess Abivax SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.11

Current PE

-38.35

Overvalued PE

4.11

Undervalued PE

-20.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.43

Current EV/EBITDA

-41.86

Overvalued EV/EBITDA

14.34

Undervalued EV/EBITDA

-41.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

271.59

Current PS

376.97

Overvalued PS

957.71

Undervalued PS

-414.53

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ABVX News & Events

Events Timeline

No data

News

8.5

12-10SeekingAlpha

Rumors of Eli Lilly's Acquisition Allegedly Boost Abivax's Stock Surge

4.0

11-26NASDAQ.COM

ABVX Surpasses Average Analyst Price Target

6.0

11-24Benzinga

Truist Securities Begins Coverage of Abivax with a Buy Rating and Sets Price Target at $140

People Also Watch

Frequently Asked Questions

What is Abivax SA (ABVX) stock price today?

The current price of ABVX is 120.78 USD — it has decreased -3.8 % in the last trading day.

What is Abivax SA (ABVX)'s business?

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

What is the price predicton of ABVX Stock?

What is Abivax SA (ABVX)'s revenue for the last quarter?

Abivax SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Abivax SA (ABVX)'s earnings per share (EPS) for the last quarter?

Abivax SA. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Abivax SA (ABVX)'s fundamentals?

The market is revising Downward the revenue expectations for ABIVAX Société Anonyme (ABVX) for FY2025, with the revenue forecasts being adjusted by -6.15% over the past three months. During the same period, the stock price has changed by 40.65%.

How many employees does Abivax SA (ABVX). have?

Abivax SA (ABVX) has 0 emplpoyees as of December 15 2025.

What is Abivax SA (ABVX) market cap?

Today ABVX has the market capitalization of 9.78B USD.